The TEL‐AML1 real‐time quantitative polymerase chain reaction (PCR) might replace the antigen receptor‐based genomic PCR in clinical minimal residual disease studies 
in children with acute lymphoblastic leukaemia

No abstract is available for this paper.

• Publication year

  2002

• Venue

  British Journal of Haematology

• Publication date

  2002-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/j.1365-2141.2002.03228.xPMID 11841400
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy

  2001cited by this paper
• Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia.

  2000cited by this paper
• Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group.

  2000cited by this paper
• Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia

  2000influential reference
• Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.

  2000cited by this paper
• Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reavtion identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse.

  2000cited by this paper
• Minimal residual disease studies are beneficial in the follow‐up of TEL/AML1 patients with B‐precursor acute lymphoblastic leukaemia

  2000cited by this paper
• Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.

  2000cited by this paper
• Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease

  1999cited by this paper
• Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real‐time RT‐PCR exemplified by t(12;21) TEL‐AML1 fusion transcript

  1999cited by this paper
• Suitable DNA isolation method for the detection of minimal residual disease by PCR techniques

  1999cited by this paper
• Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.

  1998cited by this paper
• Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia

  1998cited by this paper
• Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

  1998cited by this paper
• Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes

  1998influential reference
• Clonal diversity of Ig and T-cell-receptor gene rearrangements identifies a subset of childhood B-precursor acute lymphoblastic leukemia with increased risk of relapse.

  1998cited by this paper
• Prognostic Significance of TEL/AML1 Fusion Transcript in Childhood B‐Precursor Acute Lymphoblastic Leukemia

  1998cited by this paper
• Clonal Diversity of Ig and T-Cell-Receptor Gene Rearrangements Identifies a Subset of Childhood B-Precursor Acute Lymphoblastic Leukemia With Increased Risk of Relapse

  1998cited by this paper
• Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.

  1998cited by this paper
• A prospective study of minimal residual disease in childhood B‐lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse

  1997cited by this paper
• Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DIR segments, inverted D segments, "minor" D segments or D-D recombination.

  1997cited by this paper
• Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.

  1996cited by this paper
• TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia.

  1996cited by this paper
• High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.

  1996cited by this paper
• Clonal evolution of immunoglobulin heavy chain rearrangements in childhood B-precursor acute lymphoblastic leukemia after engraftment in SCID mice.

  1996cited by this paper
• IgH/TCR delta PCR oligonucleotide liquid hybridization, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL.

  1995cited by this paper
• Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.

  1995influential reference
• The human immunoglobulin VH repertoire.

  1995cited by this paper
• TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.

  1995cited by this paper
• Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.

  1995cited by this paper
• A Complete Map of the Human Immunoglobulin VH Locus

  1995cited by this paper
• Significance of lymphoblasts in cerebrospinal fluid in newly diagnosed pediatric acute lymphoblastic malignancies with bone marrow involvement: possible benefit of dexamethasone.

  1995cited by this paper
• High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia.

  1995cited by this paper
• Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes.

  1994cited by this paper
• Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.

  1994cited by this paper
• Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia.

  1992cited by this paper
• Complex rearrangements within the human J delta‐C delta/J alpha‐C alpha locus and aberrant recombination between J alpha segments.

  1988cited by this paper
• Minimal Residual Disease in Acute Leukemia

  1984cited by this paper

• Comparison of two qPCR-based assays for detection of minimal residual disease in B-precursor acute lymphoblastic leukemia harboring three major fusion transcripts.

  2021cites this paper
• [Clinical significance of monitoring ETV6-RUNX1 fusion gene expression in children with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].

  2017cites this paper
• 伴ETV6-RUNX1融合基因阳性的儿童急性淋巴细胞白血病患者造血干细胞移植后监测该融合基因的意义

  2017cites this paper
• Outcome and Prognostic Factors for ETV6/RUNX1 Positive Pediatric Acute Lymphoblastic Leukemia Treated at a Single Institution in Korea

  2016cites this paper
• Evaluation of the Bone Marrow After Therapy

  2011cites this paper
• Methods of minimal residual disease (MRD) detection in childhood haematological malignancies

  2010cites this paper
• Minimal Residual Disease Studies in Acute Lymphoblastic Leukemia

  2008cites this paper
• TEL/AML1 Fusion Gene in Childhood Acute Lymphoblastic Leukemia in Southern Taiwan

  2008cites this paper
• Automated detection of residual leukemic cells by consecutive immunolabeling for CD10 and fluorescence in situ hybridization for ETV6/RUNX1 rearrangement in childhood acute lymphoblastic leukemia.

  2007cites this paper
• Prognostic Significance of Molecular Follow-up by Qualitative and Real-Time Quantitative Reverse-Transcriptase Polymerase Chain Reaction in TEL/AML1–Positive Childhood Acute Lymphoblastic Leukemia

  2007cites this paper
• Resolution of ambiguous low‐level positive quantitative polymerase chain reaction results in TEL‐AML1 positive ALL using a post‐PCR fluorescent oligoligation method *

  2006cites this paper
• Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.

  2005cites this paper
• TEL/AML1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL

  2005cites this paper
• Improvement of gene expression analysis by RQ-PCR technology: addition of BSA

  2004cites this paper
• Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods.

  2004cites this paper
• T cell receptor BV repertoires using real time PCR: a comparison of SYBR green and a dual-labelled HuTrec fluorescent probe.

  2004cites this paper
• Cancer Diagnostics

  2004cites this paper
• Molecular Diagnostics in Neoplastic Hematopathology

  2004cites this paper
• Acute Lymphoblastic Leukemia and Lymphoma

  2004cites this paper
• Determination of minimal residual disease in leukaemia patients

  2003cites this paper
• Identification and characterisation of clonal incomplete T-cell-receptor Vdelta2-Ddelta3/Ddelta2-Ddelta3 rearrangements by denaturing high-performance liquid chromatography and subsequent fragment collection: implications for minimal residual disease monitoring in childhood acute lymphoblastic leuke

  2003cites this paper
• Real-time quantitative polymerase chain reaction (RO-PCR) using the LightCycler: a rapid, high-throughput method for detecting and quantifying fusion transcripts in childhood leukaemias for disease stratification and prognostication.

  2003cites this paper
• Identification and characterisation of clonal incomplete T-cell-receptor Vδ2–Dδ3/Dδ2-Dδ3 rearrangements by denaturing high-performance liquid chromatography and subsequent fragment collection: implications for minimal residual disease monitoring in childhood acute lymphoblastic leukemia

  2003cites this paper
• Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia

  2003cites this paper
• Acute lymphoblastic leukemia.

  2002cites this paper
• Preclinical validation of a monochrome real-time multiplex assay for translocations in childhood acute lymphoblastic leukemia.

  2002cites this paper
• Real-time PCR for monitoring minimal residual disease and chimerism in patients after allogeneic transplantation

  2002cites this paper
• Polymerase chain reaction (PCR)‐ and reverse transcription PCR‐based minimal residual disease detection in long‐term follow‐up of childhood acute lymphoblastic leukaemia

  2002cites this paper
• Aus der Universitäts Klinik für Kinderheilkunde und Jugendmedizin Tübingen Abteilung Kinderheilkunde I mit Poliklinik

  2002cites this paper